The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP: 1.An Expert Insights on Recent Advancements in LS-SCLC

EP: 2.The Key Updates in the Treatment of ES-SCLC

EP: 3.An Expert Perspectives on Tarlatamab in ES-SCLC

EP: 4.Looking Ahead With SCLC: ADCs and Other Novel Agents

EP: 5.The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP: 7.The New Targeted Approaches in Unresectable Early-Stage NSCL

EP: 8.Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP: 9.Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP: 10.Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations

Now Viewing

EP: 11.The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP: 12.Tailoring Immunotherapy Strategies for the Advanced NSCLC

Video content above is prompted by the following:

• What are your thoughts on the emerging data surrounding novel HER2-targeted agents, and how may they impact the future treatment landscape for NSCLC?
• Beamion LUNG-1 (zongertinib): Ruiter G, et al. WCLC 2024. Abs PL04.04
• SOHO-1 (BAY 2927088): Le X, et al. WCLC 2024. Abs PL04.03 
• Briefly comment on the eNRGy trial andFDA approval (December 2024) ofzenocutuzumab for advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion. (Schram AM, et al. ESMO 2023. Abs 1315MO; FDA.gov, FDA approves zenocutuzumab for NSCLC)
• How might you incorporate this novel therapy into your clinical practice, and what factors guide your patient selection?